MA48765A - Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub - Google Patents

Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub

Info

Publication number
MA48765A
MA48765A MA048765A MA48765A MA48765A MA 48765 A MA48765 A MA 48765A MA 048765 A MA048765 A MA 048765A MA 48765 A MA48765 A MA 48765A MA 48765 A MA48765 A MA 48765A
Authority
MA
Morocco
Prior art keywords
activity
sulfonamide substituted
dub inhibitors
cyanopyrrolidines
substituted cyanopyrrolidines
Prior art date
Application number
MA048765A
Other languages
English (en)
French (fr)
Inventor
Mark Ian Kemp
Andrew Madin
Martin Lee Stockley
Michael David Woodrow
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of MA48765A publication Critical patent/MA48765A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA048765A 2017-05-31 2018-05-30 Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub MA48765A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1708652.1A GB201708652D0 (en) 2017-05-31 2017-05-31 Novel compounds and uses

Publications (1)

Publication Number Publication Date
MA48765A true MA48765A (fr) 2020-04-08

Family

ID=59270941

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048765A MA48765A (fr) 2017-05-31 2018-05-30 Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub

Country Status (7)

Country Link
US (1) US11414402B2 (enExample)
EP (1) EP3630096A1 (enExample)
JP (1) JP7221217B2 (enExample)
CN (1) CN110678176B (enExample)
GB (1) GB201708652D0 (enExample)
MA (1) MA48765A (enExample)
WO (1) WO2018220355A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014912B2 (en) 2016-09-27 2021-05-25 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018234775A1 (en) 2017-06-20 2018-12-27 Mission Therapeutics Limited Substituted cyanopyrrolidines with activity as dub inhibitors
CA3072362A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
MY209034A (en) 2018-10-05 2025-06-17 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
AU2020215510B2 (en) 2019-01-28 2025-03-06 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
CA3127590A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
EP4132925A1 (en) 2020-04-08 2023-02-15 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
MX2022014429A (es) 2020-05-28 2022-12-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
KR20230019198A (ko) 2020-06-04 2023-02-07 미션 테라퓨틱스 엘티디 Usp30 억제제로서의 활성을 갖는 n-시아노피롤리딘
HRP20250891T1 (hr) 2020-06-08 2025-09-26 Mission Therapeutics Limited 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primjenu u liječenju mitohondrijske disfunkcije, raka i fibroze
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2022159566A1 (en) * 2021-01-21 2022-07-28 Icahn School Of Medicine At Mount Sinai Benzenesulfonamide agonists of trap1 for treating organ fibrosis
EP4441044A1 (en) 2021-12-01 2024-10-09 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272467A4 (en) * 2000-04-06 2003-05-07 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
US6867221B2 (en) * 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
CA2626190A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
CA2689989A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
CL2008002430A1 (es) 2007-08-20 2009-10-16 Glaxo Group Ltd Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
WO2009129370A1 (en) * 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
CL2009000915A1 (es) * 2008-04-18 2010-04-16 Glaxo Group Ltd Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
UY31771A1 (es) * 2008-04-18 2009-09-30 Inhibidores de catepsina c
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
CN103183673B (zh) 2011-12-30 2016-09-14 浙江新和成股份有限公司 (s,s)-2,8-二氮杂双环[4,3,0]壬烷的合成方法
SG11201600159TA (en) 2013-07-31 2016-02-26 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2015179190A1 (en) 2014-05-19 2015-11-26 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
EP3148572A4 (en) 2014-05-27 2017-12-27 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
RU2717238C2 (ru) 2015-03-30 2020-03-19 Мишн Терапьютикс Лимитед Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
US10669234B2 (en) * 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
JP6959252B2 (ja) 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Dub阻害剤としての1−シアノピロリジン誘導体
US11014912B2 (en) 2016-09-27 2021-05-25 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018234775A1 (en) 2017-06-20 2018-12-27 Mission Therapeutics Limited Substituted cyanopyrrolidines with activity as dub inhibitors

Also Published As

Publication number Publication date
EP3630096A1 (en) 2020-04-08
CN110678176A (zh) 2020-01-10
GB201708652D0 (en) 2017-07-12
JP7221217B2 (ja) 2023-02-13
WO2018220355A1 (en) 2018-12-06
US20200172518A1 (en) 2020-06-04
US11414402B2 (en) 2022-08-16
JP2020521730A (ja) 2020-07-27
CN110678176B (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
EP3843714A4 (en) CD73 INHIBITORS
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
MA52413A (fr) Inhibiteurs de cd73
EP3549340A4 (en) MULTI-HYPOTHESIS FUSION MODE
IL304348A (en) Cd73 inhibitors
DK3612531T3 (da) Apoptose-inducerende midler
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
EP3423435A4 (en) SUBSTITUTED INDOL-MCL-1 INHIBITORS
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3755193A4 (en) CLEANING DEVICE
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
EP3604752A4 (en) TRACTOR
MA49006A (fr) Inhibiteurs d'ip6k
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EP3418275A4 (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
UA37876S (uk) Трактор
EP3102571A4 (en) EGFR-T790M KINASEINHIBITORS USEFUL SUBSTITUTED PYRIMIDINES
EP3604758A4 (en) TRACTOR
EP3809933A4 (en) Cleaner
EP3941635A4 (en) SHREDDER
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
EP3960060A4 (en) CLEANING DEVICE